Doxorubicin can also be used in combination with targeted therapies, such as trastuzumab (Herceptin®) or pertuzumab (Perjeta®), in breast cancers that overexpress the human epidermal growth factor receptor 2 (HER2) protein. The gene discussed is ERBB2; the disease is breast carcinoma.